Company Description
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally.
The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product.
It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions.
In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions.
electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
| Country | United States |
| Founded | 2005 |
| IPO Date | Jun 22, 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Daniel Goldberger |
Contact Details
Address: 200 Forge Way, Suite 205 Rockaway, New Jersey 07866 United States | |
| Phone | 973 290 0097 |
| Website | electrocore.com |
Stock Details
| Ticker Symbol | ECOR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001560258 |
| CUSIP Number | 28531P103 |
| ISIN Number | US28531P2020 |
| Employer ID | 20-3454976 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Daniel S. Goldberger | Chief Executive Officer and Director |
| Dr. Thomas J. Errico M.D. | Founder and Independent Director |
| Joshua S. Lev | Chief Financial Officer |
| Brian M. Posner CPA, MBA. | Consultant |
| Manuel A. Marques | Senior Vice President of Operations |
| Donald Melnikoff | Senior Vice President of Engineering, Regulatory and Compliance |
| Mitch Deshon | Vice President of Global Sales and Business Development |
| Dr. Peter S. Staats M.B.A., M.D. | Chief Medical Officer |
| Amanda Yanuklis | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 6, 2025 | 10-Q | Quarterly Report |
| Aug 6, 2025 | 8-K | Current Report |
| Jul 24, 2025 | EFFECT | Notice of Effectiveness |
| Jul 18, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jul 17, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 16, 2025 | 8-K/A | [Amend] Current report |
| Jul 9, 2025 | SCHEDULE 13G/A | Filing |
| Jun 5, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | SCHEDULE 13D/A | Filing |
| May 14, 2025 | SCHEDULE 13D | Filing |